Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

BACKGROUND: Preclinical studies have documented antitumor activity of PARP inhibition both in vitro and in vivo, against Ewing sarcoma cells. This study aimed to translate that observation into a clinical trial to assess the efficacy and tolerability of olaparib, a PARP inhibitor, in patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Choy, Edwin, Butrynski, James E, Harmon, David C, Morgan, Jeffrey A, George, Suzanne, Wagner, Andrew J, D’Adamo, David, Cote, Gregory M, Flamand, Yael, Benes, Cyril H, Haber, Daniel A, Baselga, Jose M, Demetri, George D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230717/
https://www.ncbi.nlm.nih.gov/pubmed/25374341
http://dx.doi.org/10.1186/1471-2407-14-813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230717/
https://www.ncbi.nlm.nih.gov/pubmed/25374341
http://dx.doi.org/10.1186/1471-2407-14-813

Ejemplares similares